Using the proposed combination of [18F]florbetapir (SUVR >1.228) and CSF p-tau (>45 pg/ml) thresholds predictive of imminent metabolic decline, out of 33 individuals with preclinical AD, 17 (14%) had both biomarkers above the thresholds. The gene discussed is MAPT; the disease is Alzheimer disease.